Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849935 · ClinicalTrials.gov registry record
abioSCOPE PSP Reference Range Study; Extension of AB-PSP-003
A clinical trial, sponsored by Abionic.
- Completed
- Registry status
- 61
- Enrollment target
NCT05849935: Completed study, sponsored by Abionic.
NCT05849935 is a clinical trial that has completed, run by Abionic. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05849935 has completed, sponsored by Abionic.
- COMPLETED
- Registry status
- 61 participants
- Enrollment target
Study Summary
This is a monocentric, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.
Interventions
- DIAGNOSTIC_TEST abioSCOPE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2023-07-31 |
What the finished NCT05849935 record still lists
NCT05849935 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which abioSCOPE is the first listed.
NCT05849935 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05849935 about?
NCT05849935 is a clinical study titled "abioSCOPE PSP Reference Range Study; Extension of AB-PSP-003". This is a monocentric, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.
What is the current status of trial NCT05849935?
This trial is currently completed. The enrollment target is 61 participants. The study started on 2023-07-17. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT05849935?
The interventions under investigation include: abioSCOPE (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05849935?
This trial is sponsored by Abionic, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI